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Abstract
Background: The response to treatment varies among patients with multiple myeloma and markers for prediction
of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation
of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potential influence of different
polymorphisms in the CYP enzymes on the outcome of treatment.
Methods: Data was analyzed from 348 patients undergoing high-dose treatment and stem cell support in
Denmark in 1994 to 2004. Clinical information on relapse treatment in 243 individual patients was collected. The
patients were genotyped for the non-functional alleles CYP2C19*2 and CYP2D6*3, *4, *5 (gene deletion), *6, and
CYP2D6 gene duplication.
Results: In patients who were treated with bortezomib and were carriers of one or two defective CYP2D6 alleles
there was a trend towards a better time-to-next treatment. We found no association between the number of
functional CYP2C19 and CYP2D6 alleles and outcome of treatment with cyclophosphamide or thalidomide. Neither
was the number of functional CYP2C19 and CYP2D6 alleles associated with neurological adverse reactions to
thalidomide and bortezomib.
Conclusion: There was no association between functional CYP2C19 and CYP2D6 alleles and treatment outcome in
multiple myeloma patients treated with cyclophosphamide, thalidomide or bortezomib. A larger number of
patients treated with bortezomib are needed to determine the role of CYP2D6 alleles in treatment outcome.
Background
The response to anticancer dru g sv a r i e sc o n s i d e r a b l y
between patients, suggesting that individualized treat-
ment might improve the response [1]. The individual
differences in the efficacy of many drugs may reflect
that genetic variations and genotype-based drug
prescription represents a promising future means of
individualizing drug treatment. Notably, genetic poly-
morphisms in enzymes implicated in drug metabolism
represent a source of individual variation in drug
responses. Among the drug metabolizing enzymes, the
cytochrome P450 enzymes, such as CYP2C19 and
CYP2D6, play a particularly important role [2].
Cyclophosphamide and thalidomide are used for the
treatment of multiple myeloma and other cancers. The
therapeutic effect is dependent on metabolic activation
by CYP enzymes. Several CYP450 enzymes are impli-
cated in the activation of cyclophosphamide including
CYP2C19 [3]. This enzyme may play an even more sig-
nificant role in the activation of thalidomide [4]. Borte-
zomib is a therapeutic proteasome inhibitor used for
treatment of multiple myeloma (MM) and lymphoma.
In contrast to cyclophosphamide and thalidomide, the
activity of bortezomib is not dependent on biotransfor-
mation. The primary route of metabolism of bortezomib
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CYP3A4 with contribution from CYP2D6 and several
other CYP450 enzymes [5,6]. This abolishes the effect of
bortezomib since the boron atom is necessary for the
inhibition of the 26 S proteasome.
High-dose treatment with stem cell support (HDT) is
standard treatment of younger patients with MM. Stem
cells are harvested at regeneration following treatment
with high-dose cyclophosphamide and granulocyte col-
ony-stimulating factor. At recurrence of disease after
HDT, new effective modalities such as thalidomide and
bortezomib are now available and incorporation of these
drugs has improved overall survival (OS) [7]. In Den-
mark, thalidomide was introduced as treatment at
relapse of MM in 2000 and bortezomib was introduced
for compassionate use in 2002.
Significant differences in the outcome of treatment of
MM are observed. This variation can be explained by
biological aspects of the tumour, tumour burden at
diagnosis, immune response and by differences in
response to therapy caused by genetic variations in the
drug metabolizing enzymes or genes involved in DNA
repair or inflammation [8-10].
In this study, we analyzed the influence of commonly
occurring functional polymorphisms in CYP2C19 and
CYP2D6 on treatment outcome in relation to high-dose
cyclophophamide and treatment with thalidomide or
bortezomib at recurrence of disease.
Methods
Subjects, clinical data, response criteria, and eligibility cri-
teria have previously been described in detail [9-11].
Briefly, patients diagnosed with MM, and treated with
high-dose melphalan and stem cell support from August
1994 to August 2004, were recruited from four participat-
ing centres in Denmark. Peripheral blood stem cells were
harvested at regeneration after cyclophosphamide priming
and G-CFS, and the patients hereafter underwent high-
dose chemotherapy with melphalan (200 mg/m
2) followed
by stem cell support. Information on treatment at relapse
was obtained from the medical reports from February to
May 2008.
Staging was according to Durie and Salmon and
the International Staging System (ISS). Time-to-treat-
ment failure (TTF) and OS were calculated from
date of stem cell infusion to date of progression or
death, respectively. TTF was used as follow-up after
HDT. Time-to-next treatment (TNT) was used as
follow-up after relapse treatment and was defined as
the period from start of relapse treatment to start of
new relapse treatment, progression without new
treatment or death. Duration of treatment was from
initiation of relapse treatment to cessation of
treatment.
The retrospective collection of data allowed analyzing
response to treatment as 1) partial response or more
and 2) no change or progressive disease. Partial response
was defined by a reduction of at least 50% in the initial
serum M-protein concentration and a reduction of light
chain proteinuria to less than 0.2 g/24 h. No change
was defined as not meeting the criteria of partial
response or progression. Progression was defined by a
more than 25% increase in serum M-protein or 25%
increase in immunoglobulin levels above upper normal
levels, confirmed by 2 separate measurements at least
one month apart. Increase in bone marrow infiltration
of plasma cells by 25%, increase of Bence-Jones protei-
nuria to more than 1.0 g/24 hr or other signs of pro-
gression such as hypercalcemia, progressive skeletal
disease or soft-tissue plasmacytoma were also consid-
ered as progression. The occurrence of other malignan-
cies and death without progression was regarded as
events not related to progression. These patients were
included in the analysis of OS.
Adverse reactions were noted as peripheral neuropa-
thy caused by treatment with thalidomide or bortezo-
mib. The degree of neurological adverse reactions were
summarized as follows: level 1; no dose reduction at
treatment, level 2; dose reduction due to neurological
adverse reactions and level 3; cessation of treatment due
to neurological adverse reactions.
The present study was approved by the Danish Ethical
Committee (01-158/03).
Statistical methods
SPSS statistical software was used for all calculations
(SPSS for Windows, Rel. 14.0.0. 2005, Chicago: SPSS
Inc.) and R statistical software, version 2.9.2 (R Founda-
tion for Statistical Computing, 2009, Vienna, Austria).
All tests were two-sided and p-values < 0.05 were
regarded as statistically significant. Fisher’s exact test
was used for comparing categorical variables and Mann-
Whitney test was used to detect differences in the distri-
bution of continuous variables. The Kaplan-Meier
m e t h o da n dt h el o gr a n kt e s tw e r eu s e dt oc o m p a r e
TTF and OS between groups. For OS and TTF, Cox
proportional hazard model was used for adjustment for
prognostic factors. For treatment duration, linear regres-
sion analysis was used for adjustment for prognostic fac-
tors. For treatment response, logistic regression analysis
was used for adjustment for prognostic factors. Statisti-
cal corrections for multiple testing were not carried out
since none of the p values in our study reached signifi-
cance at the 5% level. In power calculation the sample
size and hazard ration (HR) were calculated with a
power of 80% and a two-sided level of significance at
0.05. Power calculations were based on the proportion
of events found in this study.
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DNA for analysis was purified from peripheral blood
mononuclear cells by the salting out method [12] or
from paraffin embedded tissue by phenol extraction as
described elsewhere [13].
Genotyping of single nucleotide polymorphisms
Determination of CYP2D6 gene deletion and duplication
was based upon long distance PCR determination of
CYP2D6 gene deletion [14] and duplication [15]. Typing
of the remaining polymorphisms was carried out using
commercially available 5′-exonuclease dependent assays
with proprietary amplification primers and allele-specific
fluorescent labeled probes. (Applied Biosystems, Foster
City, CA, USA).
Patients were categorized according to their number
of functional alleles; CYP 2C19: absence of functional
alleles, poor metabolizers (PM); one functional allele,
intermediate metabolizers (IM) and two normal alleles,
extensive metabolizers with normal capacity of the
enzyme (EM). A similar approach was used for classifi-
cation of CYP2D6 genotypes with the supplementation
of an additional class consisting of genotypes with more
than two functional CYP2D6 genes reflecting duplica-
tion, ultra rapid metabolizers (UM).
Results
Three-hundred and forty-eight patients were treated
with HDT and stem cell support. The median follow-up
of all patients still alive was 93.4 months (54.6-174.2
months). The median OS was 69.8 months (60.5-81.6
months). The median TTF was 27.7 months (23.4 to
30.8 months). Two-hundred and forty-three patients
suffered from relapse which required treatment. The
median follow-up time of patients with relapse was 91.4
months (60-158.8 months) and the median OS after
HDT was 56.3 months. The genotype distributions of
CYP2C19 and CYP2D6 in relation to prognostic markers
are presented in table 1. In CYP2C19 ad i f f e r e n c ei n
creatinine levels (p = 0.03) and ISS stage (p = 0.04), was
found between EM and IM + PM. In CYP2D6 ad i f f e r -
ence was found in sex in relation to UM + EM and IM
+ PM (p = 0.04).
The study included 348 myeloma patients treated with
high-dose treatment and stem cell support. The CYP
2C19 genotypes were determined in 339 patients and
CYP2D6 in 228 patients. The allele frequency of
CYP2C19*2 was 0.109. The allele frequencies of
CYP2D6 alleles *3, *4, *5, *6 and CYP2D6 gene duplica-
tion were 0.013, 0.219, 0.038, 0.006 and 0.015, respec-
tively. These frequencies are in accordance with data
from other Northern and Western European popula-
tions [16]. Successful analysis and data of response after
high-dose cyclophosphamide was available for 247
patients. No differences in response, TTF after HDT
and OS was found (Table 2, Table 3 and Figure 1).
Adjustment for prognostic markers such as age, sex, b2-
microglobuloin, creatinine and Durie-Salmon stage did
not influence response to cyclophosphamide treatment.
In CYP2C19, 266 patients were EM and 73 patients
were IM or PM. With this distribution, power calcula-
tions revealed that we had 80% chance of detecting an
HR of 1.5 and 1.6 for TTF and OS, respectively. For
CYP2D6 127 patients were UM or EM and 101 patients
were IM or PM. With this distribution, power calcula-
tions revealed that we had 80% chance of detecting an
Table 1 Characteristics of the patient population subdivided by the polymorphisms in CYP2C19 and CYP2D6
CYP2C19
EM
CYP2C19
IM + PM
P value CYP2D6
UM + EM
CYP2D6
IM + PM
P value
Age 55 (28-69) 57 (31-66) 0.80 56 (28-69) 56 (35-68) 0.5
b2-micro-globulin 3.7 (1.2-55.6) 4.9 (1.5-22.0) 0.09 4.1 (1.3-36.0) 3.7 (1.2-56.6) 0.9
Creatinine 1.1 (0.6-9.4) 1.3 (0.5-8.4) 0.03 1.1 (0.5-9.4) 1.1 (0.7-6.9) 0.8
Albumin 3.5 (0.3-5.3) 3.3 (1.6-5.3) 0.07 3.5 (0.3-5.2) 3.5 (0.3-5.0) 0.5
Durie-Salmon Stage
I 29 (11%) 5 (7%) 0.4 10 (8%) 11 (11%) 0.5
II 62 (24%) 14 (19%) 25 (20%) 23 (23%)
III 167 (65%) 54 (74%) 89 (72%) 64 (65%)
ISS
I 46 (25%) 8 (16%) 0.04 18 (22%) 21 (28%) 0.5
II 78 (42%) 15 (31%) 33 (41%) 24 (32%)
III 60 (33%) 26 (53%) 30 (37%) 29 (39%)
Sex
male 149 (56%) 48 (66%) 0.2 68 (54%) 68 (67%) 0.04
female 116 (44%) 25 (34%) 59 (46%) 33 (33%)
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nations of metabolizer status for in CYP2C19 and
CYP2D6 were analysed for the effect of high-dose treat-
ment with cyclophosphamide: 1) EM for CYP2C19 and
EM for CYP2D6,2 )P Mf o rCYP2C19 and EM for
CYP2D6,3 )E Mf o rCYP2C19 and PM for CYP2D6,4 )
PM for CYP2C19 and PM for CYP2D6.T h e r ew a sn o
difference in outcome for patients carrying the various
combinations of CYP2C19 and CYP2D6 (Figure 2).
At relapse 177 patients were treated with thalido-
mide and 74 patients were treated with bortezomib.
Some patients treated with thalidomide were later trea-
ted with bortezomib. Clinical data and successful
analysis were available for 166 patients treated with
thalidomide and 65 patients treated with bortezomib
(CYP2C19 (65 patients) and CYP2D6 (45 patients)). In
this setting, age was a prognostic factor at relapse. In
patients treated with thalidomide, age did not influence
treatment outcome. However, in patients treated with
bortezomib older age was associated with poor out-
come (p = 0.04). Adjustment for age in patients treated
with bortezomib did not change the results. For
patients treated with thalidomide, we found no differ-
ence in response to treatment or TNT in carriers of
defective CYP 2C19 and CYP2D6 alleles (Table 3). For
CYP2C19, 78 patients were EM and 22 patients were
IM or PM. With this distribution, power calculations
revealed that we had 80% chance of detecting an HR
of 1.7 and 1.8 for TTF and OS, respectively. Very few
data were available for patients treated with bortezo-
mib. A trend towards a better TNT was found for
patients treated with bortezomib who were carriers of
one or two defective CYP2D6 alleles, i.e. patients clas-
sified as IM and PM (p = 0.07). For patients treated
with bortezomib the genotype distribution of CYP2C19
revealed that 36 patients were EM and 13 patients
were IM or PM. With this phenotype distribution,
power calculations showed that we had 80% chance of
detecting a HR of 2.5 and 2.7 for TTF and OS, recep-
tively. For CYP2D6 21 patients were UM and EM and
16 patients were IM or PM. With this phenotype
distribution, we had 80% chance of detection a HR of
Table 2 Analysis of the effects of phenotypes on TTF
and OS
Genotype N % Median TTF
(months)
p value Median OS
(months)
p value
CYP2C19
EM 266 78 28.7 0.4
(0.4)
73.9 0.4
(0.5)
IM + PM 73 22 25.1 65.6
CYP2D6
UM + EM 127 56 30.7 0.9
(0.8)
65.9 0.2
(0.4)
IM + PM 101 44 25.4 80.7
Values in italics are adjusted for prognostic-related factors (TTF: b2-
microglobulin.
OS: b2-microglobulin, creatinine and Durie-Salmon stage) and are shown in
parentheses.
Table 3 Phenotypes in CYP2C19 and CYP2D6 and outcome of treatment with cyclophosphamide, thalidomide and
bortezomib
Treatment Genotypes
classes
CR + PR
(%)
NC + PD
(%)
P value Duration
of treatment,
months
P value TTF
1/TNT
2
months
P value OS
months
P value
Cyclophosphamide CYP2C19
EM vs. 164 (78) 46 (22) 0.7 NR NR 28.7 0.4 73.9 0.4
IM + PM 23 (75) 14 (24) 25.1 (0.4) 65.6 (0.5)
Thalidomide CYP2C19
EM vs. 78 (62) 48 (38) 0.5 7.4 0.9 10.5 0.6 62.4 0.8
IM + PM 22 (53) 18 (45) 7.0 7.4 65.6
Bortezomib CYP2C19
EM 36 (73) 13 (27) 0.5 3.8 0.6 8.8 0.9 83.4 0.9
IM + PM 13 (27) 3 (13) (0.3) (0.6) 7.8 (0.7) 74.0 (0.9)
CYP2D6
UM + EM 21 (81) 5 (19) 1 4.2 0.8 7.8 0.07 69.7 0.12
IM + PM 16 (84) 3 (16) (0.9) (0.9) 11.3 (0.2) 96.1 (0.2)
NR, not relevant; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra rapid metabolizer;
CR, complete response; PR, partial response; NC, no change; PD, progressive disease. TTF, time-to-treatment failure;
TNT, time-to-next treatment
1) TTF is used for evaluation of efficacy of treatment with cyclophosphamide
2) TNT is used for evaluation of efficacy of treatment with thalidomide and bortezomib.
For treatment with cyclophosphamide values in italics are adjusted for prognostic markers: TTF: b2-microglobulin; OS: b2-microglobulin, creatinine and Durie-
Salmon stage. At relapse age was a prognostic marker. No influence of age was found for patients treated with thalidomide. For treatment with bortezomib
values in italics are adjusted for age at start of relapse treatment and are shown in parentheses.
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Figure 1 Kaplan-Meier plots of TTF and OS in all patients treated with high-dose treatment in relation to the CYP2C19 (A) and CYP2D6
(B) polymorphisms. The numbers at risk at 0, 24, 48, 72 and 96 months are presented below the figure. A: The green line represents extensive
metabolizers (EM) and the blue line represents intermediate metabolizers (IM) and poor metabolizers (PM). B: The green line represents EM and
ultra rapid metabolizers (UM) and the blue line represents patients with IM and PM status.
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Page 5 of 82.6 and 2.7 for TTF and OS, respectively. Finally, no
association was found between CYP phenotypes and
treatment with either thalidomide or bortezomib in
relation to neurological adverse reactions (Table 4).
Using the genotype distribution of CYP2C19 found in
this study, power calculations showed that 283 events
were required for significant findings for a HR of 1.5.
With the proportion of events in our study, sample
size should be 473 for OS and 359 for TTF. With a
larger HR of 2.0, 97 events were required, leading to a
sample size of 162 and 123 for TTF and OS, respec-
tively. Similar calculations, using the distribution of
CYP2D6, showed that a sample size of 194 events were
required for a HR of 1.5 and a sample size of 324 for
O S ,a n das a m p l es i z eo f2 4 6f o rT T F .W i t haH Ro f
2.0, 66 events were required which implies a sample
size of 111 for OS and 85 for TTF.
Discussion
We examined the influence of genetic variation in genes
encoding CYP2D6 and CYP2C19 on the outcome of
treatment of MM patients with high-dose cyclophospha-
mide, thalidomide and bortezomib. A trend towards bet-
ter outcome was observed for the CYP2D6 IM and PM
phenotype status in response to treatment with bortezo-
mib, perhaps reflecting a slower inactivation of this drug
in patients with defective CYP2D6 alleles. CYP2C19
A. CYP2C19/CYP2D6
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Figure 2 Kaplan-Meier plots of TTF and OS in all patients treated with high-dose treatment using combinations of genotypes
CYP2C19 and CYP2D6. The numbers at risk at 0, 24, 48, 72 and 96 months are presented below the figure. 1) EM for CYP2C19 and EM for
CYP2D6 (solid green line); 2) PM for CYP2C19 and EM for CYP2D6 (solid blue line); 3) EM for CYP2C19 and PM for CYP2D6 (dashed green line); 4)
PM for CYP2C19 and PM for CYP2D6 (dashed blue line).
Table 4 Neurologic adverse reactions of thalidomide and
bortezomib in relation to phenotype in CYP2C19 C and
CYP2D6
Parameter CYP2C19
EM
(%)
CYP2C19
IM + PM
(%)
P
value
CYP2D6
UM +
EM
(%)
CYP2D6
IM +
PM
(%)
p
value
Thalidomide
Grade 0 + 1 64 (51) 21 (52) 0.6 NR NR 0.7
Grade 2 36 (29) 5 (13)
Grade 3 26 (21) 14 (35)
Bortezomib
Grade 0 + 1 22 (46) 8 (50) 0.7 14 (54) 8 (42) 0.5
Grade 2 11 (23) 4 (25) 7 (27) 6 (32)
Grade 3 15 (31) 4 (25) 5 (19) 5 (26)
NR: not relevant
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outcome after high-dose cyclophosphamide nor with
outcome of thalidomide treatment. Moreover, neurologi-
cal adverse reactions upon treatment with thalidomide
or bortezomib did not appear to be dependent upon
CYP2C19 and CYP2D6 genotypes.
In contrast to our findings, a small Chinese study
found that myeloma patients with CYP 2C19 PM geno-
type responded less well to treatment with thalidomide
[4]. In our study, only one patient with two defective
CYP2C19 alleles was found. Interestingly, this patient
did not respond to treatment with thalidomide suggest-
ing that patients lacking CYP2C19 activity may respond
less well to treatment with thalidomide.
Other CYP enzymes than CYP2C19 and CYP2D6 are
also of relevance in relation to outcome of treatment
with cyclophosphamide, thalidomide and bortezomib. A
recent study failed to detect associations between poly-
morphisms in CYP3A4/CYP3A5 and the outcome HDT
in MM patients with HDT [17]. This may reflect that
the selected polymorphisms do not change enzyme
activity to any significant extent and that they are not in
linkage disequilibrium with any functional CYP3A4 or
CYP3A5 polymorphism.
There are limitations to the present study. Notably, a
larger patient sample would have been desirable and
p e r m i t t e du sm o r er e l i a b l yt oa s s e s st h es t r e n g t ho fa n
association between CYP2D6 genotype status and effi-
cacy of bortezomib treatment. With a larger patient
sample it would probably also have been possible to
validate the association between treatment with thalido-
mide and CYP2C19 genotype status detected among
Chinese patients [4]. Several CYP enzymes are involved
in metabolism of cyclophosphamide, thalidomide and
bortezomib. It is therefore possible that design of indivi-
dualized treatments require determination of additional
genotypes [18].
Conclusions
In conclusion, we found no association between
CYP2C19 and CYP2D6 polymorphisms on treatment
effect by cyclophosphamide, thalidomide and bortezo-
mib in patients with multiple myeloma after HDT with
stem cell support. However, a larger number of patients
treated with bortezomib are needed to exclude the effect
of CYP2D6 polymorphisms on treatment outcome.
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